VERTEX PHARMACEUTICALS INC / MA
For the period ended Sep 30, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 3, 2026
What changed in Risk Factors?
Read the current filingPrevious report: 10-Q
Period ended 2026-06-30; filed 2026-08-04.
0000875320-26-000259
Item 1A. Risk FactorsCurrent report: 10-Q
Period ended 2026-09-30; filed 2026-11-03.
0000875320-26-000291
Item 1A. Risk FactorsThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 76 previous paragraphs and 73 current paragraphs.
52 unchanged; 15 reworded; 6 added; 9 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 0 previous and 0 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Added paragraphs (6)
Current report
FDA’s review of our biologics license application for accelerated approval of povetacicept with an assigned PDUFA
Current report
anticipated potential of atumelnant, and that Crinetics will contribute to the diversity of our pipeline and support our
Removed paragraphs (9)
Previous report
material adverse effect on our business. The Crinetics Acquisition may not be completed for a number of reasons, including
Previous report
the need to satisfy customary closing conditions, the need for antitrust and/or other regulatory approvals, as well as potential
Previous report
disputes or litigation that may arise. We provide no assurance that the Crinetics Acquisition will occur or that the closing
Previous report
conditions to the Crinetics Acquisition will be satisfied in a timely manner or at all. Our realization of the value from the
Previous report
regulatory approval, including our expectations regarding the FDA’s review of our BLA for accelerated approval of
Previous report
•our expectations, plans and anticipated timeline for the pending Crinetics Acquisition, including regarding Crinetics’
Reworded paragraphs (15)
Previous wording
We may be unable to complete the Crinetics Acquisition, successfully integrate Crinetics’ business, or realize the
Current wording
We may be unable to successfully integrate Crinetics’ business, or realize the potential commercial benefits of the
Previous wording
potential commercial benefits of the strategic acquisition, which could adversely affect our business and financial
Current wording
strategic acquisition, which could adversely affect our business and financial condition.
Previous wording
Our inability to complete the Crinetics Acquisition or to successfully integrate the Crinetics business could havea
Current wording
Our inability to successfully integrate the Crinetics business could have a material adverse effect on our business. Our
Previous wording
Crinetics Acquisition relies on successful integration of its operations. We may not be able to integrate Crinetics’ business
Current wording
realization of the value from the Crinetics Acquisition relies on successful integration of its operations. We may not be able
Previous wording
successfully into our existing business, make Crinetics’ business profitable, retain key employees or realize anticipated cost
Current wording
to integrate Crinetics’ business successfully into our existing business, make Crinetics’ business profitable, retain key
Previous wording
savings or synergies, if any, from the acquisition, which could adversely affect our business and financial condition. Further,
Current wording
employees or realize anticipated cost savings or synergies, if any, from the acquisition, which could adversely affect our
Previous wording
our ongoing business may be disrupted, and our management's attention may be diverted by integration activities. In addition,
Current wording
business and financial condition. Further, our ongoing business may be disrupted, and our management's attention may be
Previous wording
the anticipated benefits of the Crinetics Acquisition depend on revenues from PALSONIFY and the commercial potential of
Current wording
diverted by integration activities. In addition, the anticipated benefits of the Crinetics Acquisition depend on revenues from
Previous wording
atumelnant. If PALSONIFY does not achieve the sales, market acceptance, or other commercial performance we expect, if
Current wording
PALSONIFY and the commercial potential of atumelnant. If PALSONIFY does not achieve the sales, market acceptance, or
Previous wording
development ofatumelnant is delayed or terminated, or if we fail to obtain approval or fail to successfully commercialize
Current wording
other commercial performance we expect, if development of atumelnant is delayed or terminated, or if we fail to obtain
Previous wording
atumelnant, we may not realize the expected revenue growth or income contribution from these assets on the anticipated
Current wording
approval or fail to successfully commercialize atumelnant, we may not realize the expected revenue growth or income
Previous wording
timeline, or at all, which could adversely affect our business and financial condition.
Current wording
contribution from these assets on the anticipated timeline, or at all, which could adversely affect our business and financial
Previous wording
accelerated approvals, and communications with regulatory authorities;
Current wording
accelerated approvals, and communications with regulatory authorities, including our expectations regarding the
Previous wording
business and operations, the commercial potential of PALSONIFY, and the anticipated potential of atumelnant and
Current wording
•our expectations regarding Crinetics’ business and operations, the commercial potential of PALSONIFY and the
Previous wording
•our expectations regarding cash generated by operations, our cash balance and expected generation and net interest
Current wording
•our expectations regarding cash generated by operations, our cash balance, cost of sales, interest income and interest